Sangamo Therapeutics, Inc (SGMOQ): EBITDA
-$117.28M
Year ended 2025-12-31
-$119.90M
Trailing 12 months to 2026-03-31
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$117.28M | n/m | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | -$98.86M | n/m | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | -$258.94M | n/m | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | -$189.17M | n/m | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | -$173.90M | n/m | 2024-03-13, From 2021-01-01 |
| 2020-12-31 | -$123.87M | n/m | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | -$101.25M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$74.79M | n/m | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | -$54.86M | n/m | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | -$71.56M | n/m | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | -$45.87M | n/m | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | -$26.23M | n/m | 2017-02-28, From 2014-01-01 |
| 2013-12-31 | -$26.14M | n/m | 2016-02-18, From 2013-01-01 |
| 2012-12-31 | -$21.54M | n/m | 2015-02-25, From 2012-01-01 |
| 2011-12-31 | -$35.17M | n/m | 2014-02-24, From 2011-01-01 |
| 2010-12-31 | -$24.26M | n/m | 2013-02-26, From 2010-01-01 |
| 2009-12-31 | -$18.83M | n/a | 2012-02-23, From 2009-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$117.28M | n/m |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | -$341.09M | n/m |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | -$113.26M | n/m |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | -$85.61M | n/m |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | -$50.68M | n/m |
| Scilex Holding Co (SCLX) | 2025-12-31 | -$341.38M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $237.0K | -96.2% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | -$467.65M | n/m |
| Alector, Inc. (ALEC) | 2025-12-31 | -$150.29M | n/m |
Compare SGMOQ, KYMR, CCCC, XFOR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗